Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.

CompletedOBSERVATIONAL
Enrollment

531

Participants

Timeline

Start Date

December 18, 2020

Primary Completion Date

January 17, 2022

Study Completion Date

January 17, 2022

Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
DRUG

Cetuximab

Weekly cetuximab at starting dose, that could be switched to biweekly

DRUG

Paclitaxel

Paclitaxel at starting dose of 80 mg/m2

Trial Locations (20)

15009

Centro Oncológico de Galicia, A Coruña

17007

Institut Catalá d'Oncologia (ICO) Girona, Girona

18014

Hospital Universitario Virgen de las Nieves, Granada

27003

Hospital Universitario Lucus Augusti, Lugo

28007

Hospital Universitario Gregorio Marañón, Madrid

28040

Hospital Universitario Clínico San Carlos, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

29010

Hospital Regional Universitario de Málaga, Málaga

31008

Complejo Hospitalario Navarra (PAMPLONA), Pamplona

37007

Hospital Universitario de Salamanca, Salamanca

38320

Hospital Universitario Canarias (TENERIFE), San Cristóbal de La Laguna

39008

Hospital Universitario Marques de Valdecilla, Santander

41014

Hospital Universitario Virgen de Valme, Seville

45004

Hospital Virgen de la Salud, Toledo

46026

Hospital Universitario y Politécnico La Fe, Valencia

50009

Hospital Universitario Miguel Servet, Zaragoza

07120

Hospital Universitario Son Espases, Palma de Mallorca

08916

Institut Catalá d'Oncologia (ICO) Badalona, Badalona

08908

Hospital Duran i Reynalds (ICO-Hospitalet), L'Hospitalet de Llobregat

08003

Hospital de Mar, Barcelona

All Listed Sponsors
collaborator

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

INDUSTRY

lead

Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

OTHER

NCT04672772 - Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data. | Biotech Hunter | Biotech Hunter